Quantcast

Latest medullary thyroid cancer Stories

2009-11-06 12:43:13

People living in volcanic areas may be at a higher risk for thyroid cancer, according to a new study published online November 5 in the Journal of the National Cancer Institute. The increasing incidence of thyroid cancer has been attributed to more sensitive screening, but recent evidence indicates that this may not be the only cause. Various environmental factors, such as those associated with volcanoes, have not been excluded as risk factors. To study this, Gabriella Pellegriti, M.D.,...

2009-10-19 17:12:58

In a study of patients undergoing thyroid surgery performed by a single surgeon, older adults did not appear to have more complications than younger patients, according to a report in October issue of Archives of Otolaryngology"“Head & Neck Surgery, one of the JAMA/Archives journals. The segment of the U.S. population older than 65 has increased by 90 percent during the past 30 years, according to background information in the article. "As the population ages, surgery is being...

2009-08-19 15:55:00

Journal of the American College of Surgeons study cites safer and easier operation with less scarring Using a novel robot-assisted endoscopic technique, a team of surgeons at Yonsei University College of Medicine in Seoul, Korea, has successfully treated 200 consecutive patients with thyroid cancer. The minimally invasive operation, which has several technical and cosmetic benefits that the traditional open operation does not offer, is described in the August issue of the Journal of the...

2009-05-28 10:02:34

New guidelines designed to standardize and optimize the diagnosis, treatment, and monitoring of patients with Medullary Thyroid Carcinoma (MTC), an uncommon and challenging form of thyroid cancer, have been developed by the American Thyroid Association and published online ahead of print in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The guidelines are available free online at www.liebertpub.com/thy"Following careful peer review, Thyroid has...

2008-10-23 06:00:11

Exelixis, Inc. (Nasdaq:EXEL) today announced that GlaxoSmithKline (GSK) (LSE: GSK; NYSE: GSK) has decided not to exercise its option to license XL184. GSK also informed Exelixis that it had decided not to license the earlier compounds in the collaboration, including XL281, XL228, XL820, and XL844. As a result, Exelixis retains the rights to develop, commercialize, and/or license all of the compounds, subject to payment to GSK of a 3% royalty on net sales of any product incorporating XL184....

2008-08-29 03:00:19

By Zaydfudim, Victor Stover, Daniel G; Caro, Susan W; Phay, John E Although medullary thyroid cancer (MTC) can produce adrenocorticotropic hormone (ACTH) in up to 40 per cent of cases as determined by immunohistochemistry, clinical hypercortisolism is rarely seen. We report a medullary endocrine neoplasia 2A (MEN 2A) kindred whose proband case presented with Cushing's syndrome (CS). This 51-year-old woman presented with debilitating weakness, exertional dyspnea, 50 pound weight gain, moon...

2008-07-28 06:00:25

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline (GSK) that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to GSK. Under the agreement, GSK has 90 days to review the data and decide whether to exercise its option to select the compound for further development and commercialization. If GSK selects XL184, Exelixis would receive a $55 million milestone...

2008-07-22 12:00:21

San Francisco-based biotech Exelixis has seen its shares rise after taking an investigational thyroid cancer drug into a Phase III trial. While the relatively low incidence of medullary thyroid cancer will limit the drug's commercial potential, the low barriers to market entry and high unmet need should help its chances of success, ultimately leading to a satisfactory return on development costs. The Phase III registrational trial is a randomized double-blind study evaluating XL184...

2008-07-21 12:01:26

Exelixis has initiated the Phase III registration trial of XL184 as a potential treatment for medullary thyroid cancer. The Phase III trial is a randomized, placebo-controlled, double-blinded study of XL184 as single-agent therapy in 315 patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Patients will be randomized in a 2:1 ratio to receive XL184 or placebo administered as a daily oral dose. The primary endpoint will be duration of...

2008-07-21 06:00:17

Exelixis, Inc. (Nasdaq:EXEL) announced today that the phase 3 registration trial of XL184 as a potential treatment for medullary thyroid cancer (MTC) has been initiated. XL184 is a small molecule anticancer compound targeting the MET, RET, and VEGFR2 receptor tyrosine kinases. Recently, Exelixis and the U.S. Food and Drug Administration (FDA) reached agreement on the phase 3 registration trial via the Special Protocol Assessment process. Exelixis has also discussed the trial design with...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related